TD
MCID: TRD006
MIFTS: 55

Tardive Dyskinesia (TD)

Categories: Gastrointestinal diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tardive Dyskinesia

MalaCards integrated aliases for Tardive Dyskinesia:

Name: Tardive Dyskinesia 56 74 52 53 29 71
Neuroleptic-Induced Tardive Dyskinesia 71
Lingual-Facial-Buccal Dyskinesia 71
Drug-Induced Tardive Dyskinesia 71
Linguofacial Dyskinesia 52
Tardive Oral Dyskinesia 52
Tardive Dystonia 52
Td 52

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive predisposition


HPO:

31
tardive dyskinesia:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 56 272620
MedGen 41 C0686347
SNOMED-CT via HPO 68 258211005
UMLS 71 C0152115 C0543891 C0686347 more

Summaries for Tardive Dyskinesia

NIH Rare Diseases : 52 Tardive dyskinesia is a neurological movement disorder that is caused by the long-term use of a certain type of medications called neuroleptics. Neuroleptic drugs are usually prescribed for psychiatric conditions, although they may be used to treat gastrointestinal or neurological conditions in some cases. Tardive dyskinesia is primarily characterized by repetitive involuntary movements of the jaw, lips and tongue such as grimacing; sticking out the tongue; and smacking, puckering and pursing the lips. Some affected people may also experience involuntary rapid, jerking movements (chorea) or slow, writhing movements (athetosis) of the arms and/or legs. It is unclear why some people who take neuroleptic medications develop these symptoms while others do not. Treatment for this condition varies but may include stopping or minimizing the use of neuroleptic drugs and/or taking additional medications to to reduce the severity of the symptoms.

MalaCards based summary : Tardive Dyskinesia, also known as neuroleptic-induced tardive dyskinesia, is related to lingual-facial-buccal dyskinesia and movement disease, and has symptoms including myoclonus and spasmodic torticollis. An important gene associated with Tardive Dyskinesia is NQO1 (NAD(P)H Quinone Dehydrogenase 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Monoamine GPCRs. The drugs Diphenhydramine and Zolpidem have been mentioned in the context of this disorder. Affiliated tissues include tongue, brain and eye, and related phenotypes are akathisia and tardive dyskinesia

OMIM : 56 Tardive dyskinesia is a debilitating motor disorder manifest as hyperkinetic, involuntary, repetitive movements predominantly of the orofacial region. It is a complication of treatment with so-called typical antipsychotic or neuroleptic agents, such as chlorpromazine or haloperidol, and is estimated to occur in 20 to 30% of chronic schizophrenics on long-term treatment (Thelma et al., 2008). (272620)

NINDS : 53 Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may be present.

Wikipedia : 74 Tardive dyskinesia (TD) is a disorder that results in involuntary, repetitive body movements. This may... more...

Related Diseases for Tardive Dyskinesia

Diseases related to Tardive Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 lingual-facial-buccal dyskinesia 31.6 DRD3 DRD2
2 movement disease 31.4 DRD3 DRD2 CYP2D6
3 choreatic disease 31.2 DRD3 DRD2
4 gastroparesis 30.4 DRD3 DRD2 CYP2D6
5 avoidant personality disorder 30.3 DRD3 DRD2
6 galactorrhea 30.3 DRD2 CYP2D6
7 schizoaffective disorder 30.2 HTR2A DRD3 DRD2 COMT
8 mood disorder 30.0 HTR2A DRD3 DRD2 COMT
9 paranoid schizophrenia 29.9 HTR2A COMT
10 dystonia 29.9 HTR2A DRD3 DRD2 CYP2D6 COMT
11 bipolar disorder 29.8 HTR2A DRD3 DRD2 COMT
12 neuroleptic malignant syndrome 29.8 HTR2A DRD3 DRD2 CYP2D6
13 tic disorder 29.7 HTR2A DRD3 DRD2 COMT
14 alcohol use disorder 29.7 HTR2A DRD3 DRD2 COMT
15 gilles de la tourette syndrome 29.7 HTR2A DRD3 DRD2 COMT
16 borderline personality disorder 29.6 HTR2A DRD2 COMT
17 mental depression 29.6 HTR2A DRD2 CYP2D6 COMT
18 bruxism 29.5 HTR2A DRD3 DRD2
19 personality disorder 29.5 HTR2A DRD3 DRD2 COMT
20 schizophreniform disorder 29.4 HTR2A DRD3 DRD2 COMT
21 narcolepsy 29.4 HTR2A DRD2 COMT
22 alcohol dependence 29.3 HTR2A DRD3 DRD2 COMT
23 schizophrenia 5 29.3 HTR2A DRD2 COMT
24 disease of mental health 29.3 HTR2A DRD3 DRD2 COMT
25 fibromyalgia 29.2 HTR2A DRD2 COMT
26 post-traumatic stress disorder 29.2 HTR2A DRD2 COMT
27 bipolar i disorder 29.2 HTR2A DRD3 DRD2 COMT
28 substance abuse 29.1 HTR2A DRD3 DRD2 CYP2D6 COMT
29 delusional disorder 29.1 HTR2A DRD3 DRD2 CYP2D6
30 psychotic disorder 29.0 HTR2A DRD3 DRD2 CYP2D6 COMT
31 panic disorder 28.9 HTR2A DRD3 DRD2 COMT
32 obsessive-compulsive disorder 28.7 HTR2A DRD3 DRD2 CYP2D6 COMT
33 attention deficit-hyperactivity disorder 28.6 HTR2A DRD3 DRD2 CYP2D6 COMT
34 major depressive disorder 28.5 HTR2A DRD3 DRD2 CYP2D6 CYP1A2 COMT
35 schizophrenia 28.4 NQO1 HTR2A HSPG2 DRD3 DRD2 CYP2D6
36 migraine with or without aura 1 28.4 HTR2A DRD3 DRD2 CYP2D6 COMT
37 tobacco addiction 28.3 HTR2A DRD3 DRD2 CYP1A2 COMT
38 parkinson disease, late-onset 28.1 SOD2 NQO1 HTR2A DRD3 DRD2 CYP2D6
39 anxiety 28.0 HTR2A DRD3 DRD2 CYP2D6 CYP1A2 COMT
40 autism spectrum disorder 27.9 SOD2 HTR2A DRD3 DRD2 CYP1A2 COMT
41 alzheimer disease 27.4 SOD2 NQO1 HTR2A HSPG2 DRD3 DRD2
42 drug induced dyskinesia 11.9
43 tremor 10.9
44 chorea, childhood-onset, with psychomotor retardation 10.7
45 allergic hypersensitivity disease 10.7
46 major affective disorder 8 10.7
47 major affective disorder 9 10.7
48 depression 10.7
49 huntington disease 10.7
50 major affective disorder 1 10.5

Comorbidity relations with Tardive Dyskinesia via Phenotypic Disease Network (PDN): (show all 16)


Acute Cystitis Alzheimer Disease
Anxiety Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophagitis
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Paranoid Schizophrenia
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Tardive Dyskinesia:



Diseases related to Tardive Dyskinesia

Symptoms & Phenotypes for Tardive Dyskinesia

Human phenotypes related to Tardive Dyskinesia:

31
# Description HPO Frequency HPO Source Accession
1 akathisia 31 HP:0031943
2 tardive dyskinesia 31 HP:0040141

Symptoms via clinical synopsis from OMIM:

56
Neuro:
akathisia
tardive dyskinesia
repetitive rapid body movements
chewing movements
oral-lingual-buccal dyskinesia
more
Misc:
complication of treatment with neuroleptic agents

Clinical features from OMIM:

272620

UMLS symptoms related to Tardive Dyskinesia:


myoclonus, spasmodic torticollis

MGI Mouse Phenotypes related to Tardive Dyskinesia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.17 COMT CYP1A2 DRD2 DRD3 HSPG2 HTR2A

Drugs & Therapeutics for Tardive Dyskinesia

Drugs for Tardive Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
2
Zolpidem Approved Phase 4 82626-48-0 5732
3
Promethazine Approved, Investigational Phase 4 60-87-7 4927
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
7
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
8
tannic acid Approved Phase 4 1401-55-4
9
Amisulpride Approved, Investigational Phase 4 71675-85-9, 53583-79-2 2159
10
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
11
Galantamine Approved Phase 4 357-70-0 9651
12
Ziprasidone Approved Phase 4 146939-27-7 60854
13
Clozapine Approved Phase 4 5786-21-0 2818
14
Perphenazine Approved Phase 4 58-39-9 4748
15
Fluphenazine Approved Phase 4 69-23-8 3372
16
Nicotine Approved Phase 4 54-11-5 942 89594
17
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
18
Lithium carbonate Approved Phase 4 554-13-2
19
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
20
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
21
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
22 Hypnotics and Sedatives Phase 4
23 GABA Agonists Phase 4
24 GABA-A Receptor Agonists Phase 4
25 Tranquilizing Agents Phase 4
26 Nootropic Agents Phase 4
27 Psychotropic Drugs Phase 4
28 Central Nervous System Depressants Phase 4
29 Antipsychotic Agents Phase 4
30 Dopamine Agents Phase 4
31 Dopamine D2 Receptor Antagonists Phase 4
32 Serotonin 5-HT2 Receptor Antagonists Phase 4
33 Serotonin 5-HT1 Receptor Agonists Phase 4
34 Dopamine Antagonists Phase 4
35 Serotonin Agents Phase 4
36 Dopamine agonists Phase 4
37 Serotonin Receptor Agonists Phase 4
38 Serotonin Antagonists Phase 4
39 Antidepressive Agents Phase 4
40 Serotonin Uptake Inhibitors Phase 4
41 Antiemetics Phase 4
42 Gastrointestinal Agents Phase 4
43 Omega 3 Fatty Acid Phase 4
44 Quetiapine Fumarate Phase 4 111974-72-2
45 Cholinesterase Inhibitors Phase 4
46 GABA Agents Phase 4
47 Fluphenazine depot Phase 4
48 Fluphenazine enanthate Phase 4
49 Cytochrome P-450 Enzyme Inhibitors Phase 4
50 Dopamine Uptake Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study Unknown status NCT00837707 Phase 4 aripiprazole
2 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
3 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
4 A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine
5 A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Completed NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
6 A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
7 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
8 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
9 Effect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled Trial Completed NCT02775591 Phase 4 DA-9701;DA-9701 placebo
10 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
11 Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder Completed NCT00181922 Phase 4 ziprasidone (Geodon)
12 Metabolic Effects of Newer Antipsychotics in Older Patients Completed NCT00245206 Phase 4 Aripiprazole;Olanzapine;Risperidone
13 The Effects of Aripiprazole on Patients With "Metabolic Syndrome": An Open-Label Trial Completed NCT00224822 Phase 4 Aripiprazole
14 Cerebral Mechanism Involved in Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics (IIT) Completed NCT00290121 Phase 4 Olanzapine
15 Risperidone Augmentation in Patients With Schizophrenia Partially Responsive to Clozapine Completed NCT00289861 Phase 4 Risperidone;placebo
16 Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents: Combination of Pharmacogenomics and Therapeutic Drug Monitoring Completed NCT00545467 Phase 4 Aripiprazole
17 Open-Label Comparative Study of Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Spectrum Disorder Completed NCT00181935 Phase 4 risperidone (Risperdal);olanzapine (Zyprexa)
18 Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia Completed NCT00595504 Phase 4 Ramelteon;Placebo
19 A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia Completed NCT00817648 Phase 4 Quetiapine;risperidone
20 Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial) Completed NCT00014001 Phase 4 perphenazine;olanzapine;quetiapine;risperidone;ziprasidone;clozapine;fluphenazine decanoate
21 1. The Pharmacogenetic Study of Interaction Among Antipsychotics, Readiness to Change, and Pharmacological Intervention for Smoking Cessation Among Schizophrenic Patients 2. Stages of Change and Outcomes of Nicotine Replacement Therapy in Chronic Schizophrenic Patients Completed NCT00495352 Phase 4 Hihg-doseNRT, Low-dose NRT, bupropion
22 Comparison of Combination Olanzapine and Lithium and Combination Chlorpromazine and Lithium in the Treatment of a First Manic Episode With Psychotic Features. Completed NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
23 A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Recruiting NCT03891862 Phase 4 Valbenazine;Placebo oral capsule
24 Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response Recruiting NCT03495024 Phase 4 Varenicline
25 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
26 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3 levetiracetam;placebo
27 A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00672373 Phase 3 Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
28 A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
29 A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3 NBI-98854
30 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
31 Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Completed NCT02736955 Phase 3 Valbenazine
32 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3 NBI-98854;Placebo
33 Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study Completed NCT00190008 Phase 3 piracetam
34 Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children Completed NCT00399698 Phase 3 Risperdal
35 Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
36 Pharmacokinetics, Tolerability, and Safety of Paliperidone After Repeated Intramuscular Injection of Paliperidone Palmitate in the Arm or the Buttock of Subjects With Schizophrenia Completed NCT00073320 Phase 3 Paliperidone Palmitate
37 A Double-Blind Placebo-Controlled Randomized Clinical Trial of Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood? Completed NCT00655174 Phase 3 fluvoxamine;sertraline;Placebo
38 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
39 Efficacy of Risperidone Consta for Improving Ability to Benefit From Skills Training in Schizophrenia Completed NCT00148083 Phase 3 Risperdal Consta (drug)
40 A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents Recruiting NCT03813238 Phase 3 Deutetrabenazine;Placebo
41 Effect of Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Recruiting NCT03790345 Phase 2, Phase 3 Pyridoxine;Cobalamin;Placebo Oral Tablet
42 A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT) Active, not recruiting NCT03176771 Phase 2, Phase 3 MT-5199;Placebo
43 An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Active, not recruiting NCT02198794 Phase 3 SD-809;Placebo
44 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Withdrawn NCT03254186 Phase 2, Phase 3 Propranolol Hydrochloride;Placebo Oral Tablet
45 Pyridoxal Kinase Activity in Schizophrenia Patients Without Versus With Tardive Dyskinesia Treated With Vitamin B6 Withdrawn NCT01908452 Phase 3 Pyridoxine
46 Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia Unknown status NCT00331669 Phase 2
47 Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Omega-3 Supplementation With Docosahexaenoic Acid (DHA) on Tardive Dyskinesia Unknown status NCT00621634 Phase 2
48 Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache Unknown status NCT00274170 Phase 1, Phase 2 Octreotide
49 An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) on Neuroleptic-induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder, Aged From at Least 18 Years to 80 Years. Completed NCT00175955 Phase 2 Levetiracetam
50 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered SNC-102 in Subjects With Drug-Induced Tardive Dyskinesia Completed NCT02064010 Phase 2 SNC-102;Placebo

Search NIH Clinical Center for Tardive Dyskinesia

Genetic Tests for Tardive Dyskinesia

Genetic tests related to Tardive Dyskinesia:

# Genetic test Affiliating Genes
1 Tardive Dyskinesia 29

Anatomical Context for Tardive Dyskinesia

MalaCards organs/tissues related to Tardive Dyskinesia:

40
Tongue, Brain, Eye, Pineal, Testes, Globus Pallidus, Heart

Publications for Tardive Dyskinesia

Articles related to Tardive Dyskinesia:

(show top 50) (show all 4163)
# Title Authors PMID Year
1
Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. 61 56
18781856 2008
2
Familial occurrence of tardive dyskinesia. 61 56
11722319 2001
3
Familial tardive dyskinesia. 61 56
6118067 1981
4
Association of regulatory variants of dopamine β-hydroxylase with cognition and tardive dyskinesia in schizophrenia subjects. 61
31913053 2020
5
Models of hyperkinetic disorders in primates. 61
31857131 2020
6
Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia. 61
31995674 2020
7
Identifying Tardive Dyskinesia: Risk Factors, Functional Impact, and Diagnostic Tools. 61
31944066 2020
8
Medication Options and Clinical Strategies for Treating Tardive Dyskinesia. 61
31995679 2020
9
Cumulative Burden of Illness in Veterans With Tardive Dyskinesia and Serious Mental Disorders. 61
31834084 2020
10
A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. 61
31995677 2020
11
Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia. 61
31974564 2020
12
The effects of valbenazine on tardive dyskinesia in older and younger patients. 61
31617235 2020
13
Comment on Akbar et al., "Valbenazine-induced parkinsonism". 61
31982730 2020
14
Methamphetamine use and antipsychotic-related extrapyramidal side-effects in patients with psychotic disorders. 61
31984872 2020
15
Psychosocial Implications of Tardive Dyskinesia in Patients With Mood Disorders Versus Schizophrenia. 61
31846247 2019
16
Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. 61
31613641 2019
17
Implications of Antipsychotic Use: Antipsychotic-Induced Movement Disorders, with a Focus on Tardive Dyskinesia. 61
31703784 2019
18
Earlier Diagnosis of Tardive Dyskinesia. 61
31846242 2019
19
Treatment Strategies for Tardive Dyskinesia. 61
31880872 2019
20
Cholinergic Medication for Antipsychotic-Induced Tardive Dyskinesia. 61
31487207 2019
21
FDA-Approved Medications to Treat Tardive Dyskinesia. 61
31851437 2019
22
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. 61
31296586 2019
23
Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. 61
31435866 2019
24
Analyzing Nanotheraputics-Based Approaches for the Management of Psychotic Disorders. 61
31499066 2019
25
Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats. 61
31487433 2019
26
Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia. 61
31686592 2019
27
Consumption of Aspartame Associated with Tardive Dyskinesia: New Observation. 61
31688394 2019
28
Simultaneous bilateral ulnar neuropathy: an unusual complication caused by neuroleptic treatment-induced tardive dyskinesia: A Case Report. 61
31702651 2019
29
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. 61
31688452 2019
30
[Tardive dyskinesia following discontinuation of neuroleptic therapy in 87-year-old patient]. 61
31806178 2019
31
Brexpiprazole for treatment-resistant major depressive disorder. 61
31431092 2019
32
Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive Movement Syndromes: A Naturalistic Observational Study in Patients With Psychotic Disorders. 61
31688397 2019
33
Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. 61
31347436 2019
34
Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. 61
31464152 2019
35
Tardive Dyskinesia: Treatment Update. 61
31420757 2019
36
VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications. 61
29455579 2019
37
Exploring the multifaceted neuroprotective actions of Emblica officinalis (Amla): a review. 61
30848470 2019
38
Keeping up with the clinical advances: tardive dyskinesia. 61
31482777 2019
39
Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. 61
31234240 2019
40
Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management. 61
31641566 2019
41
New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. 61
31153890 2019
42
A review and guide to drug-associated oral adverse effects-Dental, salivary and neurosensory reactions. Part 1. 61
31192500 2019
43
Liability and Failure to Warn a Patient. 61
31356297 2019
44
Metoclopramide for the treatment of diabetic gastroparesis. 61
31314613 2019
45
Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia. 61
31232207 2019
46
Tardive Dyskinesia Suppression Seen During A Catatonic State: A Case Report. 61
30119838 2019
47
The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. 61
30638073 2019
48
Comorbidity of Physical Disorders Among Patients With Severe Mental Illness With and Without Substance Use Disorders: A Systematic Review and Meta-Analysis. 61
31164045 2019
49
Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy. 61
31205194 2019
50
Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations. 61
31291209 2019

Variations for Tardive Dyskinesia

Expression for Tardive Dyskinesia

Search GEO for disease gene expression data for Tardive Dyskinesia.

Pathways for Tardive Dyskinesia

Pathways related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1 12.11 SOD2 NQO1 CYP2D6 CYP1A2
2
Show member pathways
11.65 HTR2A DRD3 DRD2
3
Show member pathways
11.59 CYP2D6 CYP1A2 COMT
4
Show member pathways
11.33 NQO1 CYP2D6 CYP1A2
5 11.26 NQO1 CYP1A2
6 11.25 NQO1 CYP1A2
7
Show member pathways
11.15 CYP2D6 CYP1A2
8 11.12 CYP2D6 CYP1A2
9
Show member pathways
11.08 CYP2D6 CYP1A2
10
Show member pathways
11.06 CYP2D6 CYP1A2
11 11 SOD2 NQO1
12
Show member pathways
10.86 NQO1 CYP1A2 COMT
13 10.84 DRD3 DRD2
14
Show member pathways
10.73 NQO1 CYP2D6 CYP1A2 COMT
15
Show member pathways
10.68 CYP2D6 CYP1A2
16 10.6 NQO1 COMT
17
Show member pathways
10.49 DRD3 DRD2 COMT
18 10.32 CYP2D6 CYP1A2

GO Terms for Tardive Dyskinesia

Cellular components related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.26 NQO1 HTR2A DRD2 COMT
2 dopaminergic synapse GO:0098691 8.62 DRD3 DRD2

Biological processes related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 10 SOD2 NQO1 CYP2D6 CYP1A2
2 response to organic cyclic compound GO:0014070 9.79 NQO1 CYP1A2 COMT
3 response to ethanol GO:0045471 9.77 NQO1 DRD3 DRD2
4 response to toxic substance GO:0009636 9.75 NQO1 DRD3 DRD2
5 xenobiotic metabolic process GO:0006805 9.74 NQO1 CYP2D6 CYP1A2
6 visual learning GO:0008542 9.71 DRD3 DRD2
7 retinol metabolic process GO:0042572 9.71 CYP2D6 CYP1A2
8 response to cocaine GO:0042220 9.71 DRD3 DRD2
9 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.71 DRD3 DRD2
10 positive regulation of cytokinesis GO:0032467 9.7 DRD3 DRD2
11 response to amphetamine GO:0001975 9.7 DRD3 DRD2
12 response to morphine GO:0043278 9.7 DRD3 DRD2
13 arachidonic acid metabolic process GO:0019369 9.69 CYP2D6 CYP1A2
14 negative regulation of blood pressure GO:0045776 9.69 DRD3 DRD2
15 arachidonic acid secretion GO:0050482 9.69 DRD3 DRD2
16 exogenous drug catabolic process GO:0042738 9.68 CYP2D6 CYP1A2
17 drug metabolic process GO:0017144 9.68 CYP2D6 CYP1A2
18 negative regulation of adenylate cyclase activity GO:0007194 9.68 DRD3 DRD2
19 long-chain fatty acid biosynthetic process GO:0042759 9.68 CYP2D6 CYP1A2
20 superoxide metabolic process GO:0006801 9.67 SOD2 NQO1
21 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.67 DRD3 DRD2
22 negative regulation of protein secretion GO:0050709 9.67 DRD3 DRD2
23 temperature homeostasis GO:0001659 9.66 HTR2A DRD2
24 dopamine receptor signaling pathway GO:0007212 9.66 DRD3 DRD2
25 synaptic transmission, dopaminergic GO:0001963 9.65 DRD3 DRD2
26 negative regulation of cytosolic calcium ion concentration GO:0051481 9.65 DRD3 DRD2
27 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 DRD3 DRD2
28 oxidative demethylation GO:0070989 9.64 CYP2D6 CYP1A2
29 prepulse inhibition GO:0060134 9.64 DRD3 DRD2
30 behavioral response to ethanol GO:0048149 9.63 DRD3 DRD2
31 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.63 DRD3 DRD2
32 positive regulation of renal sodium excretion GO:0035815 9.62 DRD3 DRD2
33 G protein-coupled receptor internalization GO:0002031 9.62 DRD3 DRD2
34 removal of superoxide radicals GO:0019430 9.61 SOD2 NQO1
35 regulation of potassium ion transport GO:0043266 9.59 DRD3 DRD2
36 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD3 DRD2
37 heterocycle metabolic process GO:0046483 9.56 CYP2D6 CYP1A2
38 drug catabolic process GO:0042737 9.55 CYP2D6 CYP1A2
39 response to drug GO:0042493 9.55 HTR2A DRD3 DRD2 CYP1A2 COMT
40 monoterpenoid metabolic process GO:0016098 9.54 CYP2D6 CYP1A2
41 regulation of dopamine secretion GO:0014059 9.54 HTR2A DRD3 DRD2
42 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.52 DRD3 DRD2
43 negative regulation of dopamine receptor signaling pathway GO:0060160 9.51 DRD3 DRD2
44 estrogen metabolic process GO:0008210 9.5 CYP2D6 CYP1A2 COMT
45 regulation of neurotransmitter uptake GO:0051580 9.49 DRD3 DRD2
46 regulation of locomotion involved in locomotory behavior GO:0090325 9.48 DRD3 DRD2
47 acid secretion GO:0046717 9.46 DRD3 DRD2
48 response to histamine GO:0034776 9.43 DRD3 DRD2
49 behavioral response to cocaine GO:0048148 9.43 HTR2A DRD3 DRD2
50 alkaloid metabolic process GO:0009820 9.4 CYP2D6 CYP1A2

Molecular functions related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.71 SOD2 NQO1 CYP2D6 CYP1A2
2 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.43 CYP2D6 CYP1A2
3 adrenergic receptor activity GO:0004935 9.37 DRD3 DRD2
4 dopamine binding GO:0035240 9.32 DRD3 DRD2
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD3 DRD2
6 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD3 DRD2
7 superoxide dismutase activity GO:0004784 8.96 SOD2 NQO1
8 drug binding GO:0008144 8.92 HTR2A DRD3 DRD2 CYP2D6

Sources for Tardive Dyskinesia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....